Skip to main content
SpringerLink
Log in

Bleomycin: low-risk therapy for good-risk testicular cancer

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. as defined by the International Germ Cell Cancer Collaborative Group (IGCCCG).

  2. Pulmonary outcomes included prolonged intubation, need for reintubation, ICU need and duration, and duration of supplemental oxygen.

  3. Operative outcomes included operative time, length of stay, estimated blood loss, and performance of concomitant procedures.

Reference

  • Calaway AC, et al. Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors. Journal of Clinical Oncology : [6 pages], 29 Aug 2018. Available from: URL: http://dx.doi.org/10.1200/JCO.18.00431

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bleomycin: low-risk therapy for good-risk testicular cancer. Reactions Weekly 1719, 5 (2018). https://doi.org/10.1007/s40278-018-51560-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-51560-6

Search

Navigation